Clinical Trial Update: RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study

View source ↗

Summary

Pfizer's rituximab biosimilar intravenous infusion (100 mg and 500 mg) was investigated in a post-marketing database study for lymphoma, and the study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Rituximab BS (rituximab)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma | Status: COMPLETED